Brought to you by 
Innodia licenses Neurochem's diabetes technology
16 Jun 2003
Executive Summary
In exchange for an undisclosed licensing fee, Canadian specialty pharmaceutical company Neurochem (focuses on CNS diseases) licensed to fellow Canadian biotech Innodia (diabetes therapeutics) the IP rights to its diabetes project, an anti-amyloid series of compounds--with ID 1567 as lead--designed to prevent the process of amyloid fibrillogenesis (a cause of cell dysfunction and death).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Innodia licenses Neurochem's diabetes technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice